ACITRETIN 10mg. IP

A synthetic retinoid belonging to the family of retinoid analogs drugs, and is widely used in moderate to severe psoriasis patients. (Xingchen Zhou, 2017) The most widely used retinoid in the treatment of psoriasis and plays an important role in dermatologic treatments. (Sunil Dogra, 2014) Elicits anti-psoriatic activity via modulation of keratinocyte proliferation and downstream anti-inflammatory pathways. (Deepak M. W. Balak, 2020) An important addition to the armamentarium of agents used to treat recalcitrant or severe forms of psoriasis. (Gollnick, 1996) An oral retinoid (derived from vitamin A) that treats severe skin disorders, such as psoriasis, and inflammatory dermatoses. (Tania Pilkington, 1992) The first‐line treatment in reactive neutrophilic dermatoses, due to its efficacy, tolerability, and absence of an immunosuppressive effect. (Rujira Rujiwetpongstorn, 2020) A safer agent due to no suppressive effect on the immune system than other systemic therapies for psoriasis such as methotrexate and cyclosporine. (Aiai Geng, 2022) Displays an inhibitory property of neutrophil migration in the treatment of neutrophilic dermatoses. (Rujira Rujiwetpongstorn, 2020) A potential therapeutic agent for the treatment of reactive neutrophilic dermatosis. (Rujira Rujiwetpongstorn, 2020) A valuable tool that is effective in all forms of psoriasis, particularly in pustular and erythrodermic variety. (Varadraj V Pai, 2019)